Mustang Bio (MBIO)
(Delayed Data from NSDQ)
$0.28 USD
-0.01 (-4.83%)
Updated Sep 10, 2024 03:59 PM ET
After-Market: $0.28 0.00 (0.07%) 7:58 PM ET
3-Hold of 5 3
F Value A Growth D Momentum C VGM
Price, Consensus and EPS Surprise
MBIO 0.28 -0.01(-4.83%)
Will MBIO be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for MBIO based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for MBIO
Mustang (MBIO) Soars 477% on Data From Rare Blood Cancer Study
Mustang (MBIO) Up 9% on Rare Blood Cancer Study's Upbeat Data
MBIO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts Think Mustang Bio, Inc. (MBIO) Could Surge 331.15%: Read This Before Placing a Bet
Wall Street Analysts Believe Mustang Bio, Inc. (MBIO) Could Rally 711.55%: Here's is How to Trade
Here's Why Mustang Bio, Inc. (MBIO) Looks Ripe for Bottom Fishing
Other News for MBIO
MindBio’s LSD Microdosing Shows Lasting Depression Relief
MindBio Announces Sustained Antidepressant Response 3-Months Post Treatment in Microdosing Depression Clinical Trials
Fortress Biotech Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
MBIO Stock Earnings: Mustang Bio Beats EPS for Q2 2024
MindBio Partners with Haywood for Investment Strategy